Complement factor H as a marker for detection of bladder cancer

Clinical Chemistry

Volumn 51, Issue 5, 2005, Pages 856-863

  Cheng, Zhu Zhu ^a   Corey, Michael J ^b   Pärepalo, Maria ^a   Majno, Sandra ^c   Hellwage, Jens ^c   Zipfel, Peter F ^c   Kinders, Robert J ^d   Raitanen, Mika ^e   Meri, Seppo ^a   Sakari Jokiranta, T ^a,f  

^a UNIVERSITY OF HELSINKI   (Finland)

^b CellExSys   (United States)

^c HANS KNÖLL INSTITUTE   (Germany)

^d CURAGEN CORPORATION   (United States)

^e SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^f UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; COMPLEMENT FACTOR H; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY X13; MONOCLONAL ANTIBODY X52; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY DETECTION; ARTICLE; BLADDER CANCER; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER PATIENT; HUMAN; HUMAN CELL; IMMUNOASSAY; LIGAND BINDING; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DOMAIN; SURFACE PLASMON RESONANCE; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; BINDING SITES, ANTIBODY; BLOOD PROTEINS; CARCINOMA, TRANSITIONAL CELL; COMPLEMENT FACTOR H; HUMANS; LIGANDS; MALE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SURFACE PLASMON RESONANCE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 20244367757     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.042192     Document Type: Article

References (30)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Del Nero A, Esposito N, Curro A, Biasoni D, Montanari E, Mangiarotti B, et al. Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test. Eur Urol 1999;35:93-7.
3. Giannopoulos A, Manousakas T, Gounari A, Constantinides C, Choremi-Papadoppulou H, Dimopoulos C. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors. J Urol 2001;166:470-5.
4. Leyh H, Hall R, Mazeman E, Blumenstein BA. Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder. Urology 1997;50:49-53.
5. Ramakumar S, Bhuiyan J, Besse JA, Roberts SG, Wollan PC, Blute ML, et al. Comparison of screening methods in the detection of bladder cancer. J Urol 1999;161:388-94.
6. Raitanen MP, Marttila T, Kaasinen E, Rintala E, Aine R, Tammela TL. Sensitivity of human complement factor H related protein (BTA stat) test and voided urine cytology in the diagnosis of bladder cancer. J Urol 2000;163:1689-92.
7. Raitanen MP, Tammela TL. Specificity of human complement factor H-related protein test (Bard BTA stat Test). Scand J Urol Nephrol 1999;33:234-6.
8. Thomas L, Leyh H, Marberger M, Bombardieri E, Bassi P, Pagano F, et al. Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem 1999;45:472-7.
9. Pode D, Shapiro A, Wald M, Nativ O, Laufer M, Kaver I. Noninvasive detection of bladder cancer with the BTA stat test. J Urol 1999;161:443-6.
10. Sarosdy MF, Hudson MA, Ellis WJ, Soloway MS, DeVere White R, Sheinfeld J, et al. Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology 1997;50:349-53.
11. Kinders R, Jones T, Root R, Bruce C, Murchison H, Corey M, et al. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res 1998;4:2511-20.
12. Ripoche J, Day AJ, Harris TJ, Sim RB. The complete amino acid sequence of human complement factor H. Biochem J 1988;249: 593-602.
13. Junnikkala S, Jokiranta TS, Friese MA, Jarva H, Zipfel PF, Meri S. Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J Immunol 2000;164:6075-81.
14. Blackmore TK, Sadlon TA, Ward HM, Lublin DM, Gordon DL. Identification of a heparin binding domain in the seventh short consensus repeat of complement factor H. J Immunol 1996;157: 5422-7.
15. Blackmore TK, Hellwage J, Sadlon TA, Higgs N, Zipfel PF, Ward HM, et al. Identification of the second heparin-binding domain in human complement factor H. J Immunol 1998;160:3342-8.
16. Pangburn MK, Atkinson MA, Meri S. Localization of the heparin-binding site on complement factor H. J Biol Chem 1991;266: 16847-53.
17. Meri S, Pangburn MK. Regulation of alternative pathway complement activation by glycosaminoglycans: specificity of the polyanion binding site on factor H. Biochem Biophys Res Commun 1994;198:52-9.
18. McRae JL, Cowan PJ, Power DA, Mitchelhill KI, Kemp BE, Morgan BP, et al. Human factor H-related protein 5 (FHR-5). A new complement-associated protein. J Biol Chem 2001;276:6747-54.
19. Zipfel PF, Jokiranta TS, Hellwage J, Koistinen V, Meri S. The factor H protein family [Review]. Immunopharmacology 1999;42:53-60.
20. Zipfel PF, Skerka C. FHL-1/reconectin: a human complement and immune regulator with cell-adhesive function [Review]. Immunol Today 1999;20:135-40.
21. Hellwage J, Jokiranta TS, Koistinen V, Vaarala O, Meri S, Zipfel PF. Functional properties of complement factor H-related proteins FHR-3 and FHR-4: binding to the C3d region of C3b and differential regulation by heparin. FEBS Lett 1999;462:345-52.
22. Jokiranta TS, Zipfel PF, Hakulinen J, Kuhn S, Pangburn MK, Tamerius JD, et al. Analysis of the recognition mechanism of the alternative pathway of complement by monoclonal anti-factor H antibodies: evidence for multiple interactions between H and surface bound C3b. FEBS Lett 1996;393:297-302.
23. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
24. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979;76: 4350-4.
25. Jokiranta TS, Solomon A, Pangburn MK, Zipfel PF, Meri S. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol 1999;163: 4590-6.
26. Jokiranta TS, Hellwage J, Koistinen V, Zipfel PF, Meri S. Each of the three binding sites on complement factor H interacts with a distinct site on C3b. J Biol Chem 2000;275:27657-62.
27. Jokiranta TS, Westin J, Nilsson UR, Nilsson B, Hellwage J, Lofas S, et al. Complement C3b interactions studied with surface plasmon resonance technique. Int Immunopharmacol 2001;1: 495-506.
28. Corey MJ, Kinders RJ, Poduje CM, Bruce CL, Rowley H, Brown LG, et al. Mechanistic studies of the effects of anti-factor H antibodies on complement-mediated lysis. J Biol Chem 2000;275:12917-25.
29. Fontaine M, Demares MJ, Koistinen V, Day AJ, Davrinche C, Sim RB, et al. Truncated forms of human complement factor H. Biochem J 1989;258:927-30.
30. Schwaeble W, Zwirner J, Schulz TF, Linke RP, Dierich MP, Weiss EH. Human complement factor H: expression of an additional truncated gene product of 43 kDa in human liver. Eur J Immunol 1987;17:1485-9.